The DOI matches its Crossref record; 165 of the 165 references it cites were found in a registry or an index.
The rebel angel: mutant p53 as the driving oncogene in breast cancer
Open accessAbstract
Breast cancer is the most frequent invasive tumor diagnosed in women, causing over 400 000 deaths yearly worldwide. Like other tumors, it is a disease with a complex, heterogeneous genetic and biochemical background. No single genomic or metabolic condition can be regarded as decisive for its formation and progression. However, a few key players can be pointed out and among them is the TP53 tumor suppressor gene, commonly mutated in breast cancer. In particular, TP53 mutations are exceptionally frequent and apparently among the key driving factors in triple negative breast cancer -the most aggressive breast cancer subgroup-whose management still represents a clinical challenge. The majority of TP53 mutations result in the substitution of single aminoacids in the central region of the p53 protein, generating a spectrum of variants ('mutant p53s', for short). These mutants lose the normal p53 oncosuppressive functions to various extents but can also acquire oncogenic properties by gain-of-function mechanisms. This review discusses the molecular processes translating gene mutations to the pathologic consequences of mutant p53 tumorigenic activity, reconciling cell and animal models with clinical outcomes in breast cancer. Existing and speculative therapeutic methods targeting mutant p53 are also discussed, taking into account the overlap of mutant and wild-type p53 regulatory mechanisms and the crosstalk between mutant p53 and other oncogenic pathways in breast cancer. The studies described here concern breast cancer models and patients-unless it is indicated otherwise and justified by the importance of data obtained in other models.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Transactivation of the EGR1 Gene Contributes to Mutant p53 Gain of Function
Weisz, L., Zalcenstein, A., Stambolsky, P., Cohen, Y., Goldfinger, N., Oren, M., & Rotter, V. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1145 · Cited by 129
RetractedHallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261
Sørlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 10,938
The basics of epithelial-mesenchymal transition
Kalluri, R., & Weinberg, R. A. (2009) · Journal of Clinical Investigation · doi:10.1172/jci39104 · Cited by 10,196
The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells
Mani, S. A., Guo, W., Liao, M.-J., Eaton, E. N., Ayyanan, A., Zhou, A. Y., Brooks, M., Reinhard, F., Zhang, C. C., Shipitsin, M., et al. (2008) · Cell · doi:10.1016/j.cell.2008.03.027 · Cited by 8,672
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
METABRIC Group, Curtis, C., Shah, S. P., Chin, S.-F., Turashvili, G., Rueda, O. M., Dunning, M. J., Speed, D., Lynch, A. G., Samarajiwa, S., et al. (2012) · Nature · doi:10.1038/nature10983 · Cited by 6,097
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649
Tumour evolution inferred by single-cell sequencing
Navin, N., Kendall, J., Troge, J., Andrews, P., Rodgers, L., McIndoo, J., Cook, K., Stepansky, A., Levy, D., Esposito, D., et al. (2011) · Nature · doi:10.1038/nature09807 · Cited by 2,598
Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations
Cho, Y., Gorina, S., Jeffrey, P. D., & Pavletich, N. P. (1994) · Science · doi:10.1126/science.8023157 · Cited by 2,551 · cited 2×
“Derived from Protein Data Bank (PDB) ID: 1TUP (33).”
BackgroundMethodCOSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer
Forbes, S. A., Bindal, N., Bamford, S., Cole, C., Kok, C. Y., Beare, D., Jia, M., Shepherd, R., Leung, K., Menzies, A., et al. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq929 · Cited by 2,278
TP53 mutations in human cancers: origins, consequences, and clinical use.
Olivier, M., Hollstein, M., & Hainaut, P. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001008 · Cited by 2,199 · cited 2×
“Taking into account the tissue and organ specificity of tumors, breast cancer is the single most frequent event in Li–Fraumeni syndrome, accounting for >25% of all tumors in affected families (13).”
BackgroundTumor spectrum analysis in p53-mutant mice
Jacks, T., Remington, L., Williams, B. O., Schmitt, E. M., Halachmi, S., Bronson, R. T., & Weinberg, R. A. (1994) · Current Biology · doi:10.1016/s0960-9822(00)00002-6 · Cited by 2,051
The clonal and mutational evolution spectrum of primary triple-negative breast cancers
Shah, S. P., Roth, A., Goya, R., Oloumi, A., Ha, G., Zhao, Y., Turashvili, G., Ding, J., Tse, K., Haffari, G., et al. (2012) · Nature · doi:10.1038/nature10933 · Cited by 1,967 · cited 1×
“A recent study conducted with highthroughput genomic approaches confirmed that in TNBCs, mutations in TP53 are more frequent than in any other oncogene or tumor suppressor, reaching 54% of samples (133).”
BackgroundPetitjean, A., Mathe, E., Kato, S., Ishioka, C., Tavtigian, S. V., Hainaut, P., & Olivier, M. (2007) · Human Mutation · doi:10.1002/humu.20495 · Cited by 1,598 · cited 1×
“mutations [4].”
p53 Status and the Efficacy of Cancer Therapy in Vivo
Lowe, S. W., Bodis, S., McClatchey, A., Remington, L., Ruley, H. E., Fisher, D. E., Housman, D. E., & Jacks, T. (1994) · Science · doi:10.1126/science.7973635 · Cited by 1,469
Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome
Olive, K. P., Tuveson, D. A., Ruhe, Z. C., Yin, B., Willis, N. A., Bronson, R. T., Crowley, D., & Jacks, T. (2004) · Cell · doi:10.1016/j.cell.2004.11.004 · Cited by 1,308
When mutants gain new powers: News from the mutant p53 field
Brosh, R., & Rotter, V. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2693 · Cited by 1,132
Modulation of microRNA processing by p53
Suzuki, H. I., Yamagata, K., Sugimoto, K., Iwamoto, T., Kato, S., & Miyazono, K. (2009) · Nature · doi:10.1038/nature08199 · Cited by 1,124
Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome
Lang, G. A., Iwakuma, T., Suh, Y.-A., Liu, G., Rao, V. A., Parant, J. M., Valentin-Vega, Y. A., Terzian, T., Caldwell, L. C., Strong, L. C., et al. (2004) · Cell · doi:10.1016/j.cell.2004.11.006 · Cited by 1,069
Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound
Bykov, V. J. N., Issaeva, N., Shilov, A., Hultcrantz, M., Pugacheva, E., Chumakov, P., Bergman, J., Wiman, K. G., & Selivanova, G. (2002) · Nature Medicine · doi:10.1038/nm0302-282 · Cited by 1,067
Pece, S., Tosoni, D., Confalonieri, S., Mazzarol, G., Vecchi, M., Ronzoni, S., Bernard, L., Viale, G., Pelicci, P. G., & Di Fiore, P. P. (2010) · Cell · doi:10.1016/j.cell.2009.12.007 · Cited by 947
Tumor Suppression in the Absence of p53-Mediated Cell-Cycle Arrest, Apoptosis, and Senescence
Li, T., Kon, N., Jiang, L., Tan, M., Ludwig, T., Zhao, Y., Baer, R., & Gu, W. (2012) · Cell · doi:10.1016/j.cell.2012.04.026 · Cited by 912
Gain of function mutations in p53
Dittmer, D., Pati, S., Zambetti, G., Chu, S., Teresky, A. K., Moore, M., Finlay, C., & Levine, A. J. (1993) · Nature Genetics · doi:10.1038/ng0593-42 · Cited by 894
Kato, S., Han, S.-Y., Liu, W., Otsuka, K., Shibata, H., Kanamaru, R., & Ishioka, C. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1431692100 · Cited by 874
O'Connor, P. M., Jackman, J., Bae, I., Myers, T. G., Fan, S., Mutoh, M., Scudiero, D. A., Monks, A., Sausville, E. A., Weinstein, J. N., et al. (1997) · PubMed · Cited by 867
Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway
Freed-Pastor, W. A., Mizuno, H., Zhao, X., Langerød, A., Moon, S.-H., Rodriguez-Barrueco, R., Barsotti, A., Chicas, A., Li, W., Polotskaia, A., et al. (2012) · Cell · doi:10.1016/j.cell.2011.12.017 · Cited by 865
p53 isoforms can regulate p53 transcriptional activity
Bourdon, J.-C., Fernandes, K., Murray-Zmijewski, F., Liu, G., Diot, A., Xirodimas, D. P., Saville, M. K., & Lane, D. P. (2005) · Genes & Development · doi:10.1101/gad.1339905 · Cited by 810
Pharmacological Rescue of Mutant p53 Conformation and Function
Foster, B. A., Coffey, H. A., Morin, M. J., & Rastinejad, F. (1999) · Science · doi:10.1126/science.286.5449.2507 · Cited by 799
Mutant p53 drives invasion by promoting integrin recycling
Muller, P. A. J., Caswell, P. T., Doyle, B., Iwanicki, M. P., Tan, E. H., Karim, S., Lukashchuk, N., Gillespie, D. A., Ludwig, R. L., Gosselin, P., et al. (2009) · Cell · doi:10.1016/j.cell.2009.11.026 · Cited by 796
A Mutant-p53/Smad Complex Opposes p63 to Empower TGFβ-Induced Metastasis
Adorno, M., Cordenonsi, M., Montagner, M., Dupont, S., Wong, C., Hann, B., Solari, A., Bobisse, S., Rondina, M. B., Guzzardo, V., et al. (2009) · Cell · doi:10.1016/j.cell.2009.01.039 · Cited by 782
The Tumor Suppressor p53 Regulates Polarity of Self-Renewing Divisions in Mammary Stem Cells
Cicalese, A., Bonizzi, G., Pasi, C. E., Faretta, M., Ronzoni, S., Giulini, B., Brisken, C., Minucci, S., Di Fiore, P. P., & Pelicci, P. G. (2009) · Cell · doi:10.1016/j.cell.2009.06.048 · Cited by 696
Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer
Morton, J. P., Timpson, P., Karim, S. A., Ridgway, R. A., Athineos, D., Doyle, B., Jamieson, N. B., Oien, K. A., Lowy, A. M., Brunton, V. G., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0908428107 · Cited by 657
Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis
Wahl, A. F., Donaldson, K. L., Faircnild, C., Lee, F. Y. F., Foster, S. A., Demers, G. W., & Galloway, D. A. (1996) · Nature Medicine · doi:10.1038/nm0196-72 · Cited by 646
The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer.
Olivier, M., Langer√∏d, A., Carrieri, P., Bergh, J., Klaar, S., Eyfjord, J., Theillet, C., Rodriguez, C., Lidereau, R., Bi√®che, I., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1029 · Cited by 589
Crystal Structure of the Tetramerization Domain of the p53 Tumor Suppressor at 1.7 Angstroms
Jeffrey, P. D., Gorina, S., & Pavletich, N. P. (1995) · Science · doi:10.1126/science.7878469 · Cited by 549
Gain of function of mutant p53 by coaggregation with multiple tumor suppressors
Xu, J., Reumers, J., Couceiro, J. R., De Smet, F., Gallardo, R., Rudyak, S., Cornelis, A., Rozenski, J., Zwolinska, A., Marine, J.-C., et al. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.546 · Cited by 543
p53 post-translational modification: deregulated in tumorigenesis
Dai, C., & Gu, W. (2010) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2010.09.002 · Cited by 523
Coping with stress: multiple ways to activate p53
Horn, H. F., & Vousden, K. H. (2007) · Oncogene · doi:10.1038/sj.onc.1210263 · Cited by 522
Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression.
Kieser, A., Weich, H. A., Brandner, G., Marmé, D., & Kölch, W. (1994) · PubMed · Cited by 511
Malkin, D. (2011) · Genes & Cancer · doi:10.1177/1947601911413466 · Cited by 508
Gaiddon, C., Lokshin, M., Ahn, J., Zhang, T., & Prives, C. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.5.1874-1887.2001 · Cited by 464
The molecular pathology of breast cancer progression
Bombonati, A., & Sgroi, D. C. (2011) · The Journal of Pathology · doi:10.1002/path.2808 · Cited by 455
p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM
Song, H., Hollstein, M., & Xu, Y. (2007) · Nature Cell Biology · doi:10.1038/ncb1571 · Cited by 439
Bullock, A. N., Henckel, J., & Fersht, A. R. (2000) · Oncogene · doi:10.1038/sj.onc.1203434 · Cited by 434
Modi, S., Stopeck, A., Linden, H., Solit, D., Chandarlapaty, S., Rosen, N., D'Andrea, G., Dickler, M., Moynahan, M. E., Sugarman, S., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0072 · Cited by 424
Di Agostino, S., Strano, S., Emiliozzi, V., Zerbini, V., Mottolese, M., Sacchi, A., Blandino, G., & Piaggio, G. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.08.013 · Cited by 418 · cited 3×
“D receptor (SK-BR-3) (44,47,89,91,168,169); altered growth and cell polarity in 3D cultures, EMT induction (MCF10A cells with introduced p53 R273H mutant) (104,121) Germline knockin (R172H)(26,27,57) No mammary carcinomas; altered tumor spectrum compared with p53 –/– and +/– (26,27);Increased mutant p53 stability and…”
BackgroundInfluentialp73 Function Is Inhibited by Tumor-Derived p53 Mutants in Mammalian Cells
Di Como, C. J., Gaiddon, C., & Prives, C. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.2.1438 · Cited by 417
Targeted rescue of a destabilized mutant of p53 by an in silico screened drug
Boeckler, F. M., Joerger, A. C., Jaggi, G., Rutherford, T. J., Veprintsev, D. B., & Fersht, A. R. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805326105 · Cited by 387
Werner, H., Karnieli, E., Rauscher, F. J., & LeRoith, D. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.16.8318 · Cited by 370
The inherent instability of mutant p53 is alleviated by Mdm2 or p16 INK4a loss
Terzian, T., Suh, Y.-A., Iwakuma, T., Post, S. M., Neumann, M., Lang, G. A., Van Pelt, C. S., & Lozano, G. (2008) · Genes & Development · doi:10.1101/gad.1662908 · Cited by 357
Minireview: IGF, Insulin, and Cancer
Gallagher, E. J., & LeRoith, D. (2011) · Endocrinology · doi:10.1210/en.2011-0231 · Cited by 349
Selivanova, G., Iotsova, V., Okan, I., Fritsche, M., Ström, M., Groner, B., Grafström, R. C., & Wiman, K. G. (1997) · Nature Medicine · doi:10.1038/nm0697-632 · Cited by 343
Li, D., Marchenko, N. D., & Moll, U. M. (2011) · Cell Death & Differentiation · doi:10.1038/cdd.2011.71 · Cited by 336
Jackson, J. G., Pant, V., Li, Q., Chang, L. L., Quintás-Cardama, A., Garza, D., Tavana, O., Yang, P., Manshouri, T., Li, Y., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.04.027 · Cited by 329
p63 and p73, the ancestors of p53
Dotsch, V., Bernassola, F., Coutandin, D., Candi, E., & Melino, G. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a004887 · Cited by 326
MDM2 is a Central Node in the p53 Pathway: 12 Years and Counting
Bond, G., Hu, W., & Levine, A. (2005) · Current Cancer Drug Targets · doi:10.2174/1568009053332627 · Cited by 308
High-Resolution Structure of the Oligomerization Domain of p53 by Multidimensional NMR
Clore, G. M., Omichinski, J. G., Sakaguchi, K., Zambrano, N., Sakamoto, H., Appella, E., & Gronenborn, A. M. (1994) · Science · doi:10.1126/science.8023159 · Cited by 307
Li, D., Marchenko, N. D., Schulz, R., Fischer, V., Velasco-Hernandez, T., Talos, F., & Moll, U. M. (2011) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-10-0534 · Cited by 297
Skinner, H. D., Sandulache, V. C., Ow, T. J., Meyn, R. E., Yordy, J. S., Beadle, B. M., Fitzgerald, A. L., Giri, U., Ang, K. K., & Myers, J. N. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2260 · Cited by 293
A Pin1/Mutant p53 Axis Promotes Aggressiveness in Breast Cancer
Girardini, J. E., Napoli, M., Piazza, S., Rustighi, A., Marotta, C., Radaelli, E., Capaci, V., Jordan, L., Quinlan, P., Thompson, A., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.06.004 · Cited by 286
Self-citationMutant p53 protein localized in the cytoplasm inhibits autophagy
Morselli, E., Tasdemir, E., Chiara Maiuri, M., Galluzzi, L., Kepp, O., Criollo, A., Vicencio, J. M., Soussi, T., & Kroemer, G. (2008) · Cell Cycle · doi:10.4161/cc.7.19.6751 · Cited by 277
Friedler, A., Hansson, L. O., Veprintsev, D. B., Freund, S. M. V., Rippin, T. M., Nikolova, P. V., Proctor, M. R., Rüdiger, S., & Fersht, A. R. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.241629998 · Cited by 268
PRIMA-1MET synergizes with cisplatin to induce tumor cell apoptosis
Bykov, V. J. N., Zache, N., Stridh, H., Westman, J., Bergman, J., Selivanova, G., & Wiman, K. G. (2005) · Oncogene · doi:10.1038/sj.onc.1208419 · Cited by 252
Wolf, D., Harris, N., & Rotter, V. (1984) · Cell · doi:10.1016/0092-8674(84)90532-4 · Cited by 249
Modulation of the Vitamin D3 Response by Cancer-Associated Mutant p53
Stambolsky, P., Tabach, Y., Fontemaggi, G., Weisz, L., Maor-Aloni, R., Sigfried, Z., Shiff, I., Kogan, I., Shay, M., Kalo, E., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.11.025 · Cited by 245
Physical and Functional Interaction between p53 Mutants and Different Isoforms of p73
Strano, S., Munarriz, E., Rossi, M., Cristofanelli, B., Shaul, Y., Castagnoli, L., Levine, A. J., Sacchi, A., Cesareni, G., Oren, M., et al. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m003360200 · Cited by 240
Different Tumor-Derived p53 Mutants Exhibit Distinct Biological Activities
Halevy, O., Michalovitz, D., & Oren, M. (1990) · Science · doi:10.1126/science.2218501 · Cited by 234
Physical Interaction with Human Tumor-derived p53 Mutants Inhibits p63 Activities
Strano, S., Fontemaggi, G., Costanzo, A., Rizzo, M. G., Monti, O., Baccarini, A., Del Sal, G., Levrero, M., Sacchi, A., Oren, M., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m201405200 · Cited by 226
Self-citationMa, C. X., Cai, S., Li, S., Ryan, C. E., Guo, Z., Schaiff, W. T., Lin, L., Hoog, J., Goiffon, R. J., Prat, A., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci58765 · Cited by 225
p63 is a suppressor of tumorigenesis and metastasis interacting with mutant p53
Melino, G. (2011) · Cell Death & Differentiation · doi:10.1038/cdd.2011.81 · Cited by 224
Ubiquitination and Degradation of Mutant p53
Lukashchuk, N., & Vousden, K. H. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.00050-07 · Cited by 223
p53-family proteins and their regulators: hubs and spokes in tumor suppression
Collavin, L., Lunardi, A., & Del Sal, G. (2010) · Cell Death & Differentiation · doi:10.1038/cdd.2010.35 · Cited by 220
Self-citationLinks between mutant p53 and genomic instability
Hanel, W., & Moll, U. M. (2012) · Journal of Cellular Biochemistry · doi:10.1002/jcb.23400 · Cited by 216
Langerød, A., Bukholm, I., Bregård, A., Lønning, P. E., Andersen, T. I., Rognum, T. O., Meling, G. I., Lothe, R. A., & Børresen‐Dale, A. (2002) · PubMed · Cited by 204
Bossi, G., Lapi, E., Strano, S., Rinaldo, C., Blandino, G., & Sacchi, A. (2006) · Oncogene · doi:10.1038/sj.onc.1209026 · Cited by 202
Mutant p53 Enhances Nuclear Factor κB Activation by Tumor Necrosis Factor α in Cancer Cells
Weisz, L., Damalas, A., Liontos, M., Karakaidos, P., Fontemaggi, G., Maor-Aloni, R., Kalis, M., Levrero, M., Strano, S., Gorgoulis, V. G., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2425 · Cited by 199
High metastatic potential in mice inheriting a targeted p53 missense mutation
Liu, G., McDonnell, T. J., Montes de Oca Luna, R., Kapoor, M., Mims, B., El-Naggar, A. K., & Lozano, G. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.8.4174 · Cited by 199
Greenblatt, M. S., Chappuis, P. O., Bond, J. P., Hamel, N., & Foulkes, W. D. (2001) · PubMed · Cited by 196
The execution of the transcriptional axis mutant p53, E2F1 and ID4 promotes tumor neo-angiogenesis
Fontemaggi, G., Dell'Orso, S., Trisciuoglio, D., Shay, T., Melucci, E., Fazi, F., Terrenato, I., Mottolese, M., Muti, P., Domany, E., et al. (2009) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1669 · Cited by 195
Kravchenko, J. E., Ilyinskaya, G. V., Komarov, P. G., Agapova, L. S., Kochetkov, D. V., Strom, E., Frolova, E. I., Kovriga, I., Gudkov, A. V., Feinstein, E., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0802091105 · Cited by 191
Chaperone-dependent stabilization and degradation of p53 mutants
Muller, P., Hrstka, R., Coomber, D., Lane, D. P., & Vojtesek, B. (2008) · Oncogene · doi:10.1038/sj.onc.1211010 · Cited by 182
Geldanamycin selectively destabilizes and conformationally alters mutated p53.
Blagosklonny, M. V., Toretsky, J. A., & Neckers, L. (1995) · PubMed · Cited by 178
Mantovani, F., Tocco, F., Girardini, J. E., Smith, P., Gasco, M., Lü, X., Crook, T., & Sal, G. D. (2007) · Nature Structural & Molecular Biology · doi:10.1038/nsmb1306 · Cited by 177
Mutant p53 mediates survival of breast cancer cells
Lim, L. Y., Vidnovic, N., Ellisen, L. W., & Leong, C.-O. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605335 · Cited by 175
Bertheau, P., Turpin, E., Rickman, D. S., Espié, M., de Reyniès, A., Feugeas, J.-P., Plassa, L.-F., Soliman, H., Varna, M., de Roquancourt, A., et al. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040090 · Cited by 173
Ohashi, S., Natsuizaka, M., Wong, G. S., Michaylira, C. Z., Grugan, K. D., Stairs, D. B., Kalabis, J., Vega, M. E., Kalman, R. A., Nakagawa, M., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4614 · Cited by 164
Sarig, R., Rivlin, N., Brosh, R., Bornstein, C., Kamer, I., Ezra, O., Molchadsky, A., Goldfinger, N., Brenner, O. J., & Rotter, V. (2010) · The Journal of Experimental Medicine · doi:10.1084/jem.20100797 · Cited by 163
Manié, É., Vincent‐Salomon, A., Lehmann‐Che, J., Pierron, G., Turpin, E., Warcoin, M., Gruel, N., Lebigot, I., Sastre‐Garau, X., Lidereau, R., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-1560 · Cited by 163
Kogan-Sakin, I., Tabach, Y., Buganim, Y., Molchadsky, A., Solomon, H., Madar, S., Kamer, I., Stambolsky, P., Shelly, A., Goldfinger, N., et al. (2010) · Cell Death and Differentiation · doi:10.1038/cdd.2010.94 · Cited by 161
Inactivation of p53 in breast cancers correlates with stem cell transcriptional signatures
Mizuno, H., Spike, B. T., Wahl, G. M., & Levine, A. J. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1017001108 · Cited by 160
Estrogen Receptor-α Binds p53 Tumor Suppressor Protein Directly and Represses Its Function
Liu, W., Konduri, S. D., Bansal, S., Nayak, B. K., Rajasekaran, S. A., Karuppayil, S. M., Rajasekaran, A. K., & Das, G. M. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.c600001200 · Cited by 160
p53 Isoforms: An Intracellular Microprocessor?
Khoury, M. P., & Bourdon, J.-C. (2011) · Genes & Cancer · doi:10.1177/1947601911408893 · Cited by 159
How Many Mutant p53 Molecules Are Needed To Inactivate a Tetramer?
Chan, W. M., Siu, W. Y., Lau, A., & Poon, R. Y. C. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.8.3536-3551.2004 · Cited by 158
MicroRNA-128-2 targets the transcriptional repressor E2F5 enhancing mutant p53 gain of function
Donzelli, S., Fontemaggi, G., Fazi, F., Agostino, S. D., Padula, F., Biagioni, F., Muti, P. C., Strano, S., & Blandino, G. (2011) · Cell Death and Differentiation · doi:10.1038/cdd.2011.190 · Cited by 154
Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8
Yan, W., Liu, S., Xu, E., Zhang, J., Zhang, Y., Chen, X., & Chen, X. (2013) · Oncogene · doi:10.1038/onc.2012.81 · Cited by 153
Garritano, S., Gemignani, F., Palmero, E. I., Olivier, M., Martel-Planche, G., Le Calvez-Kelm, F., Brugiéres, L., Vargas, F. R., Brentani, R. R., Ashton-Prolla, P., et al. (2010) · Human Mutation · doi:10.1002/humu.21151 · Cited by 153
Yamashita, H., Nishio, M., Toyama, T., Sugiura, H., Zhang, Z., Kobayashi, S., & Iwase, H. (2003) · Breast Cancer Research · doi:10.1186/bcr738 · Cited by 152
Linderholm, B. K., Lindahl, T., Holmberg, L., Klaar, S., Lennerstrand, J., Henriksson, R., & Bergh, J. C. S. (2001) · PubMed · Cited by 149
Mutational spectrum of p53 mutations in primary breast and ovarian tumors
Feki, A., & Irminger-Finger, I. (2004) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2004.07.002 · Cited by 139
Konduri, S. D., Medisetty, R., Liu, W., Kaipparettu, B. A., Srivastava, P., Brauch, H. B., Fritz, P., Swetzig, W. M., Gardner, A. E., Khan, S., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1009575107 · Cited by 137
Sayeed, A., Konduri, S. D., Liu, W., Bansal, S., Li, F., & Das, G. M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3724 · Cited by 135
Pharmacological reactivation of mutant p53: from protein structure to the cancer patient
Wiman, K. G. (2010) · Oncogene · doi:10.1038/onc.2010.188 · Cited by 134
TopBP1 Mediates Mutant p53 Gain of Function through NF-Y and p63/p73
Liu, K., Ling, S., & Lin, W.-C. (2011) · Molecular and Cellular Biology · doi:10.1128/mcb.05574-11 · Cited by 133
Bonnefoi, H. R., Piccart, M. J., Bogaerts, J., Mauriac, L., Fumoleau, P., Brain, E. G. C., Petit, T., Rouanet, P., Jassem, J., Blot, E., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70094-8 · Cited by 131
Neilsen, P. M., Noll, J. E., Suetani, R. J., Schulz, R. B., Al‐Ejeh, F., Evdokiou, A., Lane, D. P., & Callen, D. F. (2011) · Oncotarget · doi:10.18632/oncotarget.382 · Cited by 127
Gain-of-function mutant p53 upregulates CXC chemokines and enhances cell migration
Yeudall, W. A., Vaughan, C. A., Miyazaki, H., Ramamoorthy, M., Choi, M.-Y., Chapman, C. G., Wang, H., Black, E., Bulysheva, A. A., Deb, S. P., et al. (2011) · Carcinogenesis · doi:10.1093/carcin/bgr270 · Cited by 124
Tumor-derived p53 mutants induce oncogenesis by transactivating growth-promoting genes
Scian, M. J., Stagliano, K. E., Deb, D., Ellis, M. A., Carchman, E. H., Das, A., Valerie, K. C., Deb, S. P., & Deb, S. (2004) · Oncogene · doi:10.1038/sj.onc.1207553 · Cited by 120
Multiple Stress Signals Activate Mutant p53 In Vivo
Suh, Y., Post, S. M., Elizondo-Fraire, A. C., Macció, D. R., Jackson, J. G., El‐Naggar, A. K., Pelt, C. V., Terzian, T., & Lozano, G. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0459 · Cited by 120
Bourdon, J., Khoury, M. P., Diot, A., Baker, L., Fernandes, K., Aoubala, M., Quinlan, P., Purdie, C. A., Jordan, L. B., Prats, A., et al. (2011) · Breast Cancer Research · doi:10.1186/bcr2811 · Cited by 110
Weinmann, L., Wischhusen, J., Demma, M. J., Naumann, U., Roth, P., Dasmahapatra, B., & Weller, M. (2008) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4402301 · Cited by 108
Roger, L., Jullien, L., Gire, V., & Roux, P. (2010) · Journal of Cell Science · doi:10.1242/jcs.061002 · Cited by 108
Distinct pattern of p53 phosphorylation in human tumors
Minamoto, T., Buschmann, T., Habelhah, H., Matusevich, E., Tahara, H., Børresen‐Dale, A., Harris, C. C., Sidransky, D., & Ronai, Z. A. (2001) · Oncogene · doi:10.1038/sj.onc.1204458 · Cited by 100
Bull, S. B., Özçelik, H., Pinnaduwage, D., Blackstein, M. E., Sutherland, D. A. J., Pritchard, K. I., Tzontcheva, A., Sidlofsky, S., Hanna, W. M., Qizilbash, A. H., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2004.09.128 · Cited by 99
Abrogation of p53 function affects gadd gene responses to DNA base-damaging agents and starvation
ZHAN, Q., FAN, S., SMITH, M. L., BAE, I., YU, K., ALAMO, I., O'CONNOR, P. M., & FORNACE, A. J. (1996) · DNA and Cell Biology · doi:10.1089/dna.1996.15.805 · Cited by 97
Jain, A. N., Chin, K., Børresen‐Dale, A., Erikstein, B., Lønning, P. E., Kaaresen, R., & Gray, J. W. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151241198 · Cited by 93
Murphy, K. L., Dennis, A. P., & Rosen, J. M. (2000) · The FASEB Journal · doi:10.1096/fj.00-0128com · Cited by 91
King, S., Purdie, C. A., Bray, S. E., Quinlan, P., Jordan, L. B., Thompson, A. M., & Meek, D. W. (2012) · Breast Cancer Research · doi:10.1186/bcr3136 · Cited by 90
Speidel, D., Helmbold, H., & Deppert, W. (2005) · Oncogene · doi:10.1038/sj.onc.1209126 · Cited by 89
A transgenic mouse model for mammary carcinogenesis
Li, B., Murphy, K. L., Laucirica, R., Kittrell, F. S., Medina, D., & Rosen, J. M. (1998) · Oncogene · doi:10.1038/sj.onc.1201621 · Cited by 89
Ser392 Phosphorylation Regulates the Oncogenic Function of Mutant p53
Yap, D., Hsieh, J.-K., Zhong, S., Heath, V., Gusterson, B. A., Crook, T., & Lü, X. (2004) · Cancer Research · doi:10.1158/0008-5472.can-1305-2 · Cited by 87
Rahko, E. K., Blanco, G. A. C., Soini, Y., Bloigu, R., & Jukkola, A. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(02)00499-9 · Cited by 86
Zhang, Y., Yan, W., & Chen, X. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.214585 · Cited by 85
Monti, P., Perfumo, C., Bisio, A., Ciribilli, Y., Menichini, P., Russo, D., Umbach, D. M., Resnick, M. A., Inga, A., & Fronza, G. (2011) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-10-0496 · Cited by 84
Walerych, D., Olszewski, M. B., Gutkowska, M., Helwak, A., Żylicz, M., & Żylicz, M. (2009) · Oncogene · doi:10.1038/onc.2009.281 · Cited by 82
Self-citationAssociation of the germline TP53R337H mutation with breast cancer in southern Brazil
Assumpção, J. G., Seidinger, A. L., Mastellaro, M. J., Ribeiro, R. C., Zambetti, G. P., Ganti, R., Srivastava, K., Shurtleff, S. A., Pei, D., Zeferino, L. C., et al. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-357 · Cited by 82
Rahmani, M., Reese, E., Dai, Y., Bauer, C., Kramer, L. B., Huang, M., Jove, R., Dent, P., & Grant, S. (2004) · Molecular Pharmacology · doi:10.1124/mol.104.007831 · Cited by 82
Agostino, S. D., Cortese, G., Monti, O., Dell’Orso, S., Sacchi, A., Eisenstein, M., Citro, G., Strano, S., & Blandino, G. (2008) · Cell Cycle · doi:10.4161/cc.7.21.6995 · Cited by 81
Regulation of p53 by TopBP1: a Potential Mechanism for p53 Inactivation in Cancer
Liu, K., Bellam, N., Lin, H., Wang, B., Stockard, C. R., Grizzle, W. E., & Lin, W.-C. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.01140-08 · Cited by 81
Jordan, J. J., Inga, A., Conway, K., Edmiston, S. N., Carey, L., Wu, L., & Resnick, M. A. (2010) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-09-0442 · Cited by 81
Identification of GRO1 as a Critical Determinant for Mutant p53 Gain of Function
Yan, W., & Chen, X. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m900994200 · Cited by 80
The Multifaceted Roles of Autophagy in Tumors—Implications for Breast Cancer
Debnath, J. (2011) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-011-9223-3 · Cited by 80
Estrogen receptor protects p53 from deactivation by human double minute-2.
Liu, G., Schwartz, J. A., & Brooks, S. C. (2000) · PubMed · Cited by 79
Immortalization of human mammary epithelial cells transfected with mutant p53 (273his).
Gollahon, L., & Shay, J. W. (1996) · PubMed · Cited by 78
Junk, D. J., Vrba, L., Watts, G. S., Oshiro, M. M., Martinez, J. D., & Futscher, B. W. (2008) · Neoplasia · doi:10.1593/neo.08120 · Cited by 74
Végran, F., Boidot, R., Oudin, C., DeFrain, C., Rebucci, M., & Lizard‐Nacol, S. (2006) · Oncogene · doi:10.1038/sj.onc.1209784 · Cited by 73
In vitro analysis of the dominant negative effect of p53 mutants
Chêne, P. (1998) · Journal of Molecular Biology · doi:10.1006/jmbi.1998.1897 · Cited by 72
Mutant p53 gain of function is interwoven into the hallmarks of cancer
Solomon, H., Madar, S., & Rotter, V. (2011) · The Journal of Pathology · doi:10.1002/path.2988 · Cited by 71
Mutant p53 Forms a Complex with Sp1 on HIV-LTR DNA
Chicas, A., Molina, P. E., & Bargonetti, J. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.3965 · Cited by 69
Zawacka-Pankau, J., Kostecka, A., Sznarkowska, A., Hedström, E., & Kawiak, A. (2010) · Cell Cycle · doi:10.4161/cc.9.4.10668 · Cited by 67
Wijnhoven, S., Zwart, E., Speksnijder, E. N., Beems, R. B., Olive, K. P., Tuveson, D. A., Jonkers, J., Schaap, M. M., van den Berg, J., Jacks, T., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1650 · Cited by 66
Mutant p53 oncogenic functions are sustained by Plk2 kinase through an autoregulatory feedback loop
Valenti, F., Fausti, F., Biagioni, F., Shay, T., Fontemaggi, G., Domany, E., Yaffe, M. B., Strano, S., Blandino, G., & Agostino, S. D. (2011) · Cell Cycle · doi:10.4161/cc.10.24.18682 · Cited by 65
TP53 mutation patterns in breast cancers: searching for clues of environmental carcinogenesis
Olivier, M., & Hainaut, P. L. (2001) · Seminars in Cancer Biology · doi:10.1006/scbi.2001.0390 · Cited by 62
p16INK4a modulates p53 in primary human mammary epithelial cells.
Zhang, J., Pickering, C. R., Holst, C. R., Gauthier, M. L., & Tlsty, T. D. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1594 · Cited by 60
Reddy, N., Everhart, A. L., Eling, T. E., & Glasgow, W. C. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.6048 · Cited by 59
Heinlein, C., Krepulat, F., Löhler, J., Speidel, D., Deppert, W., & Tolstonog, G. V. (2007) · International Journal of Cancer · doi:10.1002/ijc.23317 · Cited by 59
Tawfik, K. O., Kimler, B. F., Davis, M., Fan, F., & Tawfik, O. W. (2011) · Human Pathology · doi:10.1016/j.humpath.2011.04.011 · Cited by 56
Menéndez, D., Inga, A., & Resnick, M. A. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0909129107 · Cited by 55
Bruno, T., Desantis, A., Bossi, G., Agostino, S. D., Sorino, C., Nicola, F. D., Iezzi, S., Franchitto, A., Benassi, B., Galanti, S., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.05.027 · Cited by 55
Gain-of-function p53 mutants have widespread genomic locations partially overlapping with p63
Martynova, E., Pozzi, S., Basile, V., Dolfini, D., Zambelli, F., Imbriano, C., Pavesi, G., & Mantovani, R. (2012) · Oncotarget · doi:10.18632/oncotarget.447 · Cited by 54
Kelavkar, U. P., & Badr, K. F. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.8.4378 · Cited by 49
Peptide Aptamers Targeting Mutant p53 Induce Apoptosis in Tumor Cells
Guida, E., Bisso, A., Fenollar‐Ferrer, C., Napoli, M., Anselmi, C., Girardini, J. E., Carloni, P., & Sal, G. D. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0137 · Cited by 49
Self-citationPosttranslational phosphorylation of mutant p53 protein in tumor development
Matsumoto, M., Furihata, M., & Ohtsuki, Y. (2006) · Medical Molecular Morphology · doi:10.1007/s00795-006-0320-0 · Cited by 47
Wijnhoven, S., Speksnijder, E. N., Liu, X., Zwart, E., vanOostrom, C. T. M., Beems, R. B., Hoogervorst, E. M., Schaap, M. M., Attardi, L. D., Jacks, T., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4681 · Cited by 46
ChIP-on-Chip Analysis of In Vivo Mutant p53 Binding To Selected Gene Promoters
Dell’Orso, S., Fontemaggi, G., Stambolsky, P., Goeman, F., Voellenkle, C., Levrero, M., Strano, S., Rotter, V., Oren, M., & Blandino, G. (2011) · OMICS A Journal of Integrative Biology · doi:10.1089/omi.2010.0084 · Cited by 44
Perez, R. E., Knights, C. D., Sahu, G., Catania, J., Kolukula, V. K., Stoler, D. L., Graessmann, A., Ogryzko, V. V., Pishvaian, M. J., Albanese, C., et al. (2010) · Journal of Cellular Physiology · doi:10.1002/jcp.22285 · Cited by 40
Aberrant expression of TopBP1 in breast cancer
Going, J. J., Nixon, C., Dornan, E. S., Boner, W., Donaldson, M. M., & Morgan, I. M. (2007) · Histopathology · doi:10.1111/j.1365-2559.2007.02622.x · Cited by 35
Epigenetic mechanisms affect mutant p53 transgene expression in WAP-mutp53 transgenic mice
Krepulat, F., Löhler, J., Heinlein, C., Hermannstädter, A., Tolstonog, G. V., & Deppert, W. (2005) · Oncogene · doi:10.1038/sj.onc.1208557 · Cited by 34
Fernandez‐Cuesta, L., Anaganti, S., Hainaut, P. L., & Olivier, M. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-0819-x · Cited by 33
Jong, Y.-J., Li, L.-H., Tsou, M.-H., Chen, Y.-J., Cheng, S. H., Wang‐Wuu, S., Tsai, S., Chen, C.-M., Huang, A. T., Hsu, M., et al. (2003) · Cancer Genetics and Cytogenetics · doi:10.1016/s0165-4608(03)00205-x · Cited by 30
Zhang, F., Throm, S. L., Murley, L. L., Miller, L. A., Zatechka, D. S., Guy, R. K., Kennedy, R. M., & Stewart, C. F. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.03.024 · Cited by 27
Cytoplasmic mutant p53 increases Bcl-2 expression in estrogen receptor-positive breast cancer cells
Pratt, M. A. C., White, D. M., Kushwaha, N., Tibbo, E., & Niu, M. Y. (2007) · APOPTOSIS · doi:10.1007/s10495-006-0023-y · Cited by 20
Deißler, H., Kafka, A., Schuster, E., Sauer, G., Kreienberg, R., & Zeillinger, R. (2004) · Oncology Reports · doi:10.3892/or.11.6.1281 · Cited by 20
Limited importance of the dominant-negative effect of TP53missense mutations
Stoczyńska-Fidelus, E., Szybka, M., Piaskowski, S., Bieńkowski, M., Hułas-Bigoszewska, K., Banaszczyk, M., Zawlik, I., Jesionek‐Kupnicka, D., Kordek, R., Liberski, P. P., et al. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-243 · Cited by 10
Cited by
Mutant p53 in Cancer: New Functions and Therapeutic Opportunities
Muller, P. A. J., & Vousden, K. H. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.01.021 · Cited by 1,545
“308 Cancer Cell 25, March 17, 2014 a2014 The Authors not surprising, because mutant p53 interacts with a wide variety of other proteins, resulting in interference in a multitude of cellular pathways, some of which are likely to contribute to metastasis (Freed-Pastor and Prives, 2012; Muller and Vousden, 2013; Walerych…”
BackgroundMutant p53 as a guardian of the cancer cell
Mantovani, F., Collavin, L., & Del Sal, G. (2019) · Cell Death & Differentiation · doi:10.1038/s41418-018-0246-9 · Cited by 775
Self-citationClinical management of breast cancer heterogeneity
Zardavas, D., Irrthum, A., Swanton, C., & Piccart, M. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.73 · Cited by 570
Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others
Sabapathy, K., & Lane, D. P. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.151 · Cited by 517
Martinez Molina, D., & Nordlund, P. (2016) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010715-103715 · Cited by 306
Metadata
- Authors
- Walerych, D., Napoli, M., Collavin, L., & Del Sal, G.
- Venue
- Carcinogenesis
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-07-20
- Volume
- 33
- Issue
- 11
- Pages
- 2007-2017
- ISSN
- 0143-3334 (ISSN-L)
- 1460-2180
- OpenAlex
- W2101063496
- Cited by
- 289
- References
- 165
- FWCI
- 12.78
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.